X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (65) 65
index medicus (56) 56
female (49) 49
male (43) 43
adult (35) 35
middle aged (32) 32
life sciences (24) 24
urology & nephrology (23) 23
aged (20) 20
organic chemistry (20) 20
hematology (17) 17
risk factors (14) 14
young adult (14) 14
chemical sciences (13) 13
chemistry, organic (13) 13
prognosis (13) 13
transplantation (13) 13
abridged index medicus (12) 12
adolescent (12) 12
human health and pathology (12) 12
medicine, general & internal (12) 12
retrospective studies (12) 12
france (11) 11
kidney transplantation (10) 10
registries (10) 10
rituximab (10) 10
treatment outcome (10) 10
aged, 80 and over (9) 9
complement (9) 9
follow-up studies (9) 9
heterocyclic compounds (9) 9
immunology (9) 9
nephrology (9) 9
pregnancy (9) 9
prospective studies (9) 9
risk (9) 9
thrombotic thrombocytopenic purpura (9) 9
atypical hemolytic uremic syndrome (8) 8
chemistry (8) 8
child (8) 8
diagnosis (8) 8
france - epidemiology (8) 8
hemolytic-uremic syndrome (8) 8
plasma-exchange (8) 8
renal transplantation (8) 8
thrombotic microangiopathy (8) 8
biopsy (7) 7
catalysis (7) 7
child, preschool (7) 7
eculizumab (7) 7
glomerulonephritis (7) 7
human necessities (7) 7
hygiene (7) 7
infant (7) 7
kidney (7) 7
medical or veterinary science (7) 7
metallurgy (7) 7
plasma exchange (7) 7
preparations for medical, dental, or toilet purposes (7) 7
acyclic or carbocyclic compounds (6) 6
acyclic, carbocyclic or heterocyclic compounds containingelements other than carbon, hydrogen, halogen, oxygen, nitrogen,sulfur, selenium or tellurium (6) 6
alkynes (6) 6
cyclosporine (6) 6
immunosuppressive agents - administration & dosage (6) 6
kidney - pathology (6) 6
microangiopathies (6) 6
thrombocytopenic purpura (6) 6
time factors (6) 6
von-willebrand-factor (6) 6
activation (5) 5
adamts13 (5) 5
analysis (5) 5
animals (5) 5
care and treatment (5) 5
chemistry, medicinal (5) 5
derivatives (5) 5
drug therapy, combination (5) 5
factor-cleaving protease (5) 5
genotype (5) 5
hemic and lymphatic diseases (5) 5
hemolytic uremic syndrome (5) 5
hemolytic-uremic syndrome - genetics (5) 5
immunosuppressive agents - therapeutic use (5) 5
ketones (5) 5
microbiology (5) 5
microwave chemistry, sonochemistry, mechanochemistry (5) 5
mutations (5) 5
nephrotic syndrome (5) 5
purpura, thrombotic thrombocytopenic - complications (5) 5
purpura, thrombotic thrombocytopenic - genetics (5) 5
research (5) 5
research article (5) 5
risk assessment (5) 5
surgery (5) 5
survival (5) 5
survival analysis (5) 5
therapy (5) 5
adamts13 protein (4) 4
age of onset (4) 4
ahus (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 04/2013, Volume 31, Issue 10, pp. 1302 - 1309
Journal Article
Journal of Allergy and Clinical Immunology, The, ISSN 0091-6749, 2017, Volume 140, Issue 5, pp. 1388 - 1393.e8
Journal Article
Journal Article
Kidney International, ISSN 0085-2538, 08/2012, Volume 82, Issue 4, pp. 454 - 464
Dense deposit disease and glomerulonephritis with isolated C3 deposits are glomerulopathies characterized by deposits of C3 within or along the glomerular... 
complement | glomerulonephritis | clinical immunology | membranoproliferative glomerulonephritis (MPGN) | LONG-TERM | HEMOLYTIC-UREMIC SYNDROME | MESANGIOCAPILLARY GLOMERULONEPHRITIS | GLOMERULONEPHRITIS TYPE-II | MACULAR DEGENERATION | FACTOR-H DEFICIENCY | GLOMERULAR-FILTRATION-RATE | UROLOGY & NEPHROLOGY | MUTATIONS | MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS | MEMBRANE COFACTOR PROTEIN | Humans | Child, Preschool | Male | Complement System Proteins - metabolism | Young Adult | Time Factors | DNA Mutational Analysis | Renal Insufficiency - immunology | Child | Glomerulonephritis, Membranoproliferative - pathology | Genetic Predisposition to Disease | Risk Assessment | Complement C3 - metabolism | Gene Frequency | Risk Factors | Glomerulonephritis - genetics | Glomerulonephritis - immunology | Glomerulonephritis - mortality | Biomarkers - blood | Kidney Glomerulus - pathology | Disease Progression | Glomerulonephritis, Membranoproliferative - genetics | Glomerulonephritis, Membranoproliferative - immunology | Phenotype | Complement Factor H - metabolism | Glomerulonephritis, Membranoproliferative - mortality | Glomerulonephritis - pathology | Adolescent | Age of Onset | Membrane Cofactor Protein - genetics | Kidney Glomerulus - immunology | Mutation | Complement Factor I - metabolism | Haplotypes | Complement C3 Nephritic Factor - genetics | Glomerulonephritis - therapy | Infant | Case-Control Studies | Adult | Complement System Proteins - genetics | Female | Membrane Cofactor Protein - metabolism | Complement Pathway, Alternative - genetics | France | Renal Insufficiency - genetics | Kaplan-Meier Estimate | Complement Factor I - genetics | Treatment Outcome | Chi-Square Distribution | Glomerulonephritis, Membranoproliferative - therapy | Biopsy | Complement C3 Nephritic Factor - metabolism | Complement Factor H - genetics
Journal Article
American Journal of Kidney Diseases, ISSN 0272-6386, 2013, Volume 63, Issue 1, pp. 40 - 48
Journal Article
Journal Article
SCIENTIFIC REPORTS, ISSN 2045-2322, 10/2019, Volume 9, Issue 1, pp. 15541 - 9
Journal Article
Journal Article
Clinical Journal of the American Society of Nephrology, ISSN 1555-9041, 2017, Volume 12, Issue 8, pp. 1237 - 1247
Background Pregnancy is associated with various forms of thrombotic microangiopathy, including hemolytic uremic syndrome. A previous small French study... 
COFACTOR PROTEIN CD46 | AUTOANTIBODIES | FETOMATERNAL INTERFACE | CELLS | FACTOR-H MUTATIONS | GENE | RARE | COMPLEMENT INHIBITOR ECULIZUMAB | UROLOGY & NEPHROLOGY | DECAY-ACCELERATING FACTOR | Recurrence | Renal Insufficiency, Chronic - etiology | Humans | Middle Aged | Postpartum Period | Plasma Exchange | Genetic Variation | Young Adult | Hemolytic-Uremic Syndrome - genetics | Time Factors | Adult | Female | Hemolytic-Uremic Syndrome - therapy | Retrospective Studies | Complement Activation - drug effects | Genetic Predisposition to Disease | Antibodies, Monoclonal, Humanized - therapeutic use | Hemolytic-Uremic Syndrome - complications | Europe | Complement Factor I - genetics | Treatment Outcome | Hemolytic-Uremic Syndrome - immunology | Disease Progression | Pregnancy | Complement Activation - genetics | Phenotype | Adolescent | Complement Inactivating Agents - therapeutic use | Pregnancy Complications - genetics | Complement Factor H - genetics | Kidney Failure, Chronic - etiology | Pregnancy Complications - immunology | Pregnancy Complications - therapy | Renal Dialysis | chemotactic factor inactivator | Follow-Up Studies | pregnancy | kidney transplantation | Thrombotic Microangiopathies | United Kingdom | eculizumab | hemolytic uremic syndrome | Antibodies, Monoclonal, Humanized | Italy | Kidney Failure, Chronic | thrombotic microangiopathy | complement | Complement Pathway, Alternative | France | Original | Atypical Hemolytic Uremic Syndrome | renal dialysis
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2017, Volume 12, Issue 5, p. e0177894
Chronic kidney disease (CKD) is a frequent and serious complication of atypical haemolytic uremic syndrome (aHUS). We aimed to develop a simple accurate model... 
THROMBOTIC-THROMBOCYTOPENIC PURPURA | IMPACT | PROGNOSTIC-FACTORS | COMPLEMENT INHIBITOR ECULIZUMAB | MULTIDISCIPLINARY SCIENCES | MICROANGIOPATHIES | MUTATIONS | PATHOPHYSIOLOGY | Atypical Hemolytic Uremic Syndrome - complications | Prognosis | Humans | Middle Aged | Risk Factors | Adult | Female | Male | Renal Insufficiency, Chronic - diagnosis | Renal Insufficiency, Chronic - complications | Decision-making | Care and treatment | Chronic kidney failure | Patient outcomes | Analysis | Risk factors | Hemolytic-uremic syndrome | Glomerular filtration rate | Transfusion | Coagulation | Alternative pathway | Cell activation | Classification | Diagnosis | Damage | Cross sections | Anemia | Mortality | Abnormalities | Regression analysis | Diacylglycerol kinase | Quality of life | Membrane proteins | Fibrin | Death | Adults | Clinical medicine | Mutation | Health risk assessment | Kidney transplantation | Membranes | Intensive care | Transplants & implants | Immunoglobulin G | Genes | Antibodies | Complement factor B | Risk | Transplantation | Activation | Complement | Bone diseases | Kinases | Complement factor I | Complement factor H | Bacteria | Lesions | Indicators | Health risks | Environmental factors | Cell membranes | CD46 antigen | Complement activation | Complement component C5 | Complement component C3 | Medical prognosis | Kidney diseases | Life Sciences | Human health and pathology | Urology and Nephrology
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2020, Volume 382, Issue 4, pp. 392 - 394
To the Editor: In their review article, Kremer Hovinga and George (Oct. 24 issue) 1 thoroughly describe the current knowledge regarding hereditary thrombotic... 
MEDICINE, GENERAL & INTERNAL | Plasma Exchange | ADAMTS13 Protein | Humans | Purpura, Thrombotic Thrombocytopenic | Pregnancy | Thrombocytopenic purpura | Thrombotic thrombocytopenic purpura
Journal Article
Clinical Journal of the American Society of Nephrology, ISSN 1555-9041, 2017, Volume 12, Issue 1, pp. 50 - 59
Background and objectives The complement inhibitor eculizumab has dramatically improved the outcome of atypical hemolytic uremic syndrome. However, the optimal... 
C3 | ADULT PATIENTS | ACTIVATION | MAINTENANCE TREATMENT | UROLOGY & NEPHROLOGY | AHUS | MUTATIONS | Recurrence | Antibodies, Monoclonal, Humanized - therapeutic use | Follow-Up Studies | Humans | Middle A